plerixafor has been researched along with Cholera Infantum in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, KC; Armand, P; Azab, AK; Basile, F; Baz, R; Boruchov, A; Chuma, S; Constantine, M; Crilley, P; Ghobrial, IM; Henrick, PM; Hornburg, KTV; Laubach, JP; Leblebjian, H; Liu, CJ; Mishima, Y; Munshi, NC; Noonan, K; Paba-Prada, C; Reyes, K; Richardson, PG; Schlossman, R; Shain, K; Trippa, L; Vredenburgh, J; Warren, D; Weller, E; Zavidij, O | 1 |
| Bolwell, BJ; DiPersio, JF; Marulkar, S; Maziarz, RT; Micallef, IN; Nademanee, AP; Partisano, AM; Stadtmauer, EA; Stiff, PJ | 1 |
| Kindwall-Keller, T | 1 |
| Ducey, EJ; Fatanmi, OO; Seed, TM; Singh, PK; Singh, VK; Wise, SY | 1 |
1 review(s) available for plerixafor and Cholera Infantum
| Article | Year |
|---|---|
Peripheral stem cell collection: from leukocyte growth factor to removal of catheter.
Topics: Allografts; Benzylamines; Blood Cell Count; Blood Component Removal; Blood Donors; Bone Marrow; Cyclams; Drug Administration Schedule; Gastrointestinal Diseases; Hematologic Neoplasms; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Histocompatibility Testing; Humans; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous | 2014 |
1 trial(s) available for plerixafor and Cholera Infantum
| Article | Year |
|---|---|
Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzylamines; Bone Marrow; Bortezomib; Combined Modality Therapy; Cyclams; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Gastrointestinal Diseases; Hematologic Diseases; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Humans; Kaplan-Meier Estimate; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Proteins; Neoplastic Stem Cells; Receptors, CXCR4; Recurrence; Salvage Therapy; Tumor Microenvironment | 2019 |
2 other study(ies) available for plerixafor and Cholera Infantum
| Article | Year |
|---|---|
Safety and efficacy of upfront plerixafor + G-CSF versus placebo + G-CSF for mobilization of CD34(+) hematopoietic progenitor cells in patients ≥60 and <60 years of age with non-Hodgkin's lymphoma or multiple myeloma.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzylamines; Blood Cell Count; Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cyclams; Double-Blind Method; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Heterocyclic Compounds; Humans; Lymphoma, Non-Hodgkin; Middle Aged; Multiple Myeloma; Neutropenia; Pain; Peripheral Blood Stem Cell Transplantation; Transplantation, Autologous; Young Adult | 2013 |
α-Tocopherol succinate- and AMD3100-mobilized progenitors mitigate radiation-induced gastrointestinal injury in mice.
Topics: alpha-Tocopherol; Animals; Antioxidants; Benzylamines; Blood Cells; Cyclams; Filgrastim; Gamma Rays; Gastrointestinal Diseases; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Heterocyclic Compounds; Intestinal Mucosa; Jejunum; Leukocytes, Mononuclear; Male; Mice; Radiation Chimera; Radiation Injuries; Radiation-Protective Agents; Recombinant Proteins | 2012 |